ARK Investment Management LLC Increases Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

ARK Investment Management LLC increased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 6.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,213,257 shares of the company’s stock after purchasing an additional 427,274 shares during the period. Twist Bioscience accounts for about 1.6% of ARK Investment Management LLC’s holdings, making the stock its 19th biggest holding. ARK Investment Management LLC owned approximately 0.12% of Twist Bioscience worth $265,881,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in TWST. Captrust Financial Advisors boosted its position in Twist Bioscience by 101.3% during the 2nd quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock worth $27,000 after purchasing an additional 382 shares during the period. Federated Hermes Inc. purchased a new stake in Twist Bioscience during the 3rd quarter worth $29,000. China Universal Asset Management Co. Ltd. boosted its position in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after purchasing an additional 721 shares during the period. US Bancorp DE boosted its position in Twist Bioscience by 257.1% during the 2nd quarter. US Bancorp DE now owns 2,050 shares of the company’s stock worth $42,000 after purchasing an additional 1,476 shares during the period. Finally, Comerica Bank acquired a new position in Twist Bioscience in the 3rd quarter worth $46,000.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the sale, the chief executive officer now owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the sale, the chief executive officer now owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The disclosure for this sale can be found here. Insiders sold a total of 8,301 shares of company stock valued at $294,282 in the last quarter. Insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $34.48 on Thursday. The firm’s 50-day simple moving average is $36.46 and its 200-day simple moving average is $28.77. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. The business had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The company’s revenue for the quarter was up 31.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.74) EPS. As a group, equities research analysts expect that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TWST shares. Barclays boosted their price objective on shares of Twist Bioscience from $30.00 to $45.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Scotiabank boosted their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a report on Monday, February 5th. Finally, The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.